Literatur
-
1
Becker G, Hatami I, Xander C. et al .
Palliative cancer care: an epidemiologic
study.
J Clin Oncol.
2011;
29
646-650
-
2
Cappuzzo F, Ciuleanu T, Stelmakh L. et al .
Erlotinib as maintenance treatment in advanced
non-small-cell lung cancer.
Lancet Oncol.
2010;
11
521-529
-
3
Cataldo V D, Gibbons D L, Perez-Soler R, Quintas-Cardama A.
Treatment
of non-small-cell lung cancer with erlotinib or gefitinib.
N
Engl J Med.
2011;
364
947-955
-
4
Ciuleanu T, Brodowicz T, Zielinski C. et al .
Maintenance pemetrexed plus best supportive
care versus placebo plus best supportive care for non-small-cell
lung cancer: a randomised, double-blind, phase 3 study.
Lancet.
2009;
374
1432-1440
-
5
Cohen M H, Johnson J R, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R.
Approval summary: erlotinib maintenance therapy of advanced/metastatic
non-small cell lung cancer (NSCLC).
Oncologist.
2010;
15
1344-1351
-
6
Davidoff A J, Tang M, Seal B, Edelman M J.
Chemotherapy and
survival benefit in elderly patients with advanced non-small-cell
lung cancer.
J Clin Oncol.
2010;
28
2191-2197
-
7
Fidias P M, Dakhil S R, Lyss A P. et al .
Phase III study of immediate
compared with delayed docetaxel after front-line therapy with gemcitabine
plus carboplatin in advanced non-small-cell lung cancer.
J
Clin Oncol.
2009;
27
591-598
-
8
Goeckenjan G, Sitter H, Thomas M. et al .
[Prevention, diagnosis, therapy,
and follow-up of lung cancer].
Pneumologie.
2010;
64 Suppl 2
e1-164
-
9
Goldstraw P, Crowley J, Chansky K. et al .
The IASLC Lung Cancer Staging Project:
proposals for the revision of the TNM stage groupings in the forthcoming
(seventh) edition of the TNM Classification of malignant tumours.
J Thorac Oncol.
2007;
2
706-714
-
10
Horn L, Pao W.
EML4-ALK: honing in on a new
target in non-small-cell lung cancer.
J Clin Oncol.
2009;
27
4232-4235
-
11
Jackman D, Pao W, Riely G J. et al .
Clinical definition of acquired resistance
to epidermal growth factor receptor tyrosine kinase inhibitors in
non-small-cell lung cancer.
J Clin Oncol.
2010;
28
357-360
-
12
Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D.
Global cancer statistics.
CA Cancer J Clin.
2011;
61
69-90
-
13
Kris M G, Johnson B E, Kwiatkowski D J. et al .
Identification
of driver mutations in tumor specimens from 1,000 patients with
lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium
(LCMC).
J Clin Oncol.
2011;
29
Suppl: abstr CRA7506
-
14
Kwak E L, Bang Y J, Camidge D R. et al .
Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer.
N Engl J Med.
2010;
363
1693-1703
-
15
Maemondo M, Inoue A, Kobayashi K. et al .
Gefitinib or chemotherapy for non-small-cell
lung cancer with mutated EGFR.
N Engl J Med.
2010;
362
2380-2388
-
16
Mitsudomi T, Morita S, Yatabe Y. et al .
Gefitinib versus cisplatin plus docetaxel
in patients with non-small-cell lung cancer harbouring mutations
of the epidermal growth factor receptor (WJTOG3405).
Lancet
Oncol.
2010;
11
121-128
-
17
Mok T S, Wu Y L, Thongprasert S. et al .
Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma.
N Engl J Med.
2009;
361
947-957
-
18
Pao W, Girard N.
New driver mutations in non-small-cell
lung cancer.
Lancet Oncol.
2011;
12
175-180
-
19
Quoix E A, Oster J, Westeel V. et al .
Weekly paclitaxel combined with monthly
carboplatin versus single-agent therapy in patients age 70 to 89.
J Clin Oncol.
2010;
28 Suppl
18s, abstr 2
-
20
Sequist L V, Heist R S, Shaw A T. et al .
SNaPshot genotyping of non-small
cell lung cancers (NSCLC) in clinical practice.
J Clin
Oncol.
2011;
29 Suppl
abstr
7518
-
21
Soon Y Y, Stockler M R, Askie L M, Boyer M J.
Duration
of chemotherapy for advanced non-small-cell lung cancer.
J
Clin Oncol.
2009;
27
3277-3283
-
22
Stinchcombe T E, Socinski M A.
Maintenance therapy
in advanced non-small cell lung cancer: current status and future
implications.
J Thorac Oncol.
2011;
6
174-182
-
23
Temel J S, Greer J A, Muzikansky. et al .
Early palliative care for patients with
metastatic non-small-cell lung cancer.
N Engl J Med.
2010;
363
733-742
-
24
The National Lung Screening
Trial Research Team .
Reduced Lung-Cancer Mortality with
low-dose computed tomographic screening.
N Engl J Med.
2011;
365
395-409
-
25
Travis W D, Brambilla E, Noguchi M. et al .
International association for the study
of lung cancer/american thoracic society/european
respiratory society international multidisciplinary classification
of lung adenocarcinoma.
J Thorac Oncol.
2011;
6
244-285
-
26
Vogelmeier C, Worth H, Pfeifer M. et al .
[Joint statement of the German
Respiratory Society and the German Roentgenological Society on the
early detection of lung cancer by low-dose CT].
Pneumologie.
2011;
65
5-6
Univ.-Prof. Dr. med. Rainer Wiewrodt
Klinik und Poliklinik für Innere
Medizin A mit den Schwerpunkten Hämatologie, Onkologie
und Pneumologie
Universitätsklinikum Münster
Albert-Schweitzer-Campus 1, Gebäude A1
48149
Münster
Phone: 0251/8344803
Fax: 0251/8344804
Email: rainer.wiewrodt@ukmuenster.de
